Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
May 26, 2021
End Date
June 14, 2026
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
May 26, 2021
End Date
June 14, 2026